LOGIN  |  REGISTER
Cue Biopharma

Pharming to participate in September investor conferences

August 24, 2023 | Last Trade: US$9.88 0.70 -6.62

LEIDEN, The Netherlands, Aug. 24, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conferences in the U.S. in the month of September:

  • 2023 Wells Fargo Healthcare Conference, Boston, September 6-8
    Sijmen de Vries, Chief Executive Officer, and Michael Levitan, VP Investor Relations and Corporate Communications, will participate in a fireside chat question and answer session on Thursday, September 7 at 16:30 ET/22:30 CET. A live webcast and replay of the fireside chat will be available in the "Upcoming Events" and "News" sections of Pharming's website.
  • H.C. Wainwright 25th Annual Global Investment Conference, New York, September 11-13
    Sijmen de Vries, Chief Executive Officer, will present on Wednesday, September 13 at 08:30 ET/14:30 CET. A live webcast and replay of the presentation will be available in the "Upcoming Events" and "News" sections of Pharming's website.
  • 2023 Cantor Global Healthcare Conference, New York, September 26-28
    Michael Levitan, VP Investor Relations and Corporate Communications, will present on Thursday, September 28 at 10:20 ET/16:20 CET.

For more information about these conferences, or to schedule a one-to-one meeting with Pharming's management team, please contact Pharming's Investor Relations team at This email address is being protected from spambots. You need JavaScript enabled to view it. or your Wells Fargo, H.C. Wainwright or Cantor representative.

About Pharming Group N.V.

Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden, Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.

For more information, visit www.pharming.com and find us on LinkedIn.

For further public information, contact:

Pharming Group, Leiden, The Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696

Heather Robertson, Investor Relations & Corporate Communications Manager
E: This email address is being protected from spambots. You need JavaScript enabled to view it.

FTI Consulting, London, UK
Victoria Foster Mitchell/Alex Shaw/Amy Byrne
T: +44 203 727 1000

LifeSpring Life Sciences Communication, Amsterdam, The Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page